The Escherichia coli enzyme ( purine nucleoside phosphorylase, PNP ) gene is delivered directly into PC3 tumors by one injection of replication -deficient human type -5 adenovirus ( Ad5 ). Expressed PNP converts the systemically administered prodrug, 6MPDR, to a toxic purine, 6MP, causing cell death. We sought to increase the specificity of recombinant Ad vectors by controlling PNP expression with the promoter region from the androgen -dependent, prostate -specific rat probasin ( Pb ) gene. To increase its activity, the promoter was combined with the SV40 enhancer ( SVPb ). Cell lines were transfected with plasmids containing both a reporter gene, under SVPb control, and a reference gene cassette to allow normalization of expression levels. Plasmids expressed $20 -fold more reporter in prostate cancer than in other cells, but surprisingly, the SVPb element was both androgen -independent and retained substantial prostate specificity. Killing by Ad5 -SVPb -PNP vector of cell lines cultured with 6MPDR for 6 days was 5 -to 10 -fold greater in prostate cancer than in liver or lung cells. In vivo, a single intratumoral injection of Ad5 -SVPb -PNP ( 4Â10 8 pfu ), followed by 6MPDR administration twice daily for 6 days, significantly suppressed the growth of human prostate tumors in nude mice and increased their survival compared to control animals. Thus, the androgen -independent, prostate -targeting Ad5 vector reduces human prostate cancer growth significantly in vitro and in vivo. This first example of an androgen -independent vector points the way toward treatment of emerging androgen -independent prostate cancer in conjunction with hormone ablation therapy at a time when the tumor burden is low.
P rostate cancer remains the second most common cancer in men. 1 Prostate surgery or targeted irradiation can cure cancer that is organ-confined, but some 60% of patients present with metastases. Endocrine therapy leads to significant periods of remission for cancer that has spread beyond the prostate, but is ineffective once the tumors become androgen -independent. Such tumors are refractory to conventional chemotherapy. Emerging gene therapy strategies may provide new approaches to treating prostate cancer.
Strategies for prostate cancer gene therapy have been based on: ( a) corrective gene replacement to restore suppressor gene activity, or to abrogate oncogene activity; ( b) immunotherapy to augment the body's immune response against prostate cancer; and ( c) cytotoxic reduction of prostate cancer by induction of apoptosis or by genedirected enzyme prodrug therapy (GDEPT ). 2, 3 As the prostate gland is not essential for survival, GDEPT can be used to target the prostate or prostate cancer cells. GDEPT involves delivering to tumors a gene for an enzyme not usually found in mammalian cells using viral vectors. 4 The perceived advantage derives from a bystander effect where comprehensive cell killing is achieved without the need to express the enzyme in all cells. 5 -8 This is important given that in vivo gene transfer efficiencies are unlikely to approach 100% with current gene delivery vectors.
Three GDEPT systems for prostate cancer are currently under investigation. The enzyme herpes simplex virus thymidine kinase ( HSVTK ) is used with the prodrug, ganciclovir ( GCV ). In HSVTK -expressing cells, GCV is converted to GCV triphosphate, which becomes incorporated into DNA during replication. 9 TK -GDEPT delivered by a replication -incompetent human Ad (Ad5 ) under the control of an RSV promoter to pre -established subcutaneous ( s.c. ) or orthotopic androgen-independent RM -1 prostate tumors in C57BL /6 mice resulted in significant suppression in tumor growth compared to mice treated with control Ads. 10, 11 Colonization of the lungs, induced by tail vein injection of RM -1 cells into mice, was also reduced after prostatic TK -GDEPT treatment, indicating that an antimetastatic effect was induced. 11 This ''distant bystander effect'' was shown to be mediated largely by asialo -GM1 + cells designated natural killer ( NK ) cells. 12 A phase I dose escalation clinical trial using Ad5 to deliver TK -GDEPT into the prostate under ultrasound guidance followed by intravenous administration of GCV produced a significant reduction in PSA levels in 3 /18 men, with minimal toxicity in 4/ 18 men. 13 Another GDEPT system uses bacterial cytosine deaminase ( CD ). The mammalian enzyme is absent or poorly expressed. In CD -expressing cells, 5 -fluorocytosine ( FC ) is converted to 5-fluorouracil (FU ) that inhibits DNA synthesis. 14, 15 Transduction of PC -3 cells in vitro by recombinant Ad5 carrying HVSTK and CD genes under the control of a human cytomegalovirus promoter sensitized the cells to killing by both GCV and 5 -FC and increased their radiation sensitivity. 16 We have focused on a GDEPT system in which the Escherichia coli enzyme, purine nucleoside phosphorylase ( PNP ), converts the prodrug, 9-( -D -2 -deoxy -erythropentofuranosyl )6-methylpurine (6MPDR ), to the toxic compound, 6 -methylpurine (6MP ). 17, 18 PNP -GDEPT has several advantages over the TK -and CD -GDEPT systems. First, unlike phosphorylated GCV, 6MP readily diffuses across cell membranes and hence generates a higher bystander activity. 17 -19 Only 1% of cells in a tissue culture dish needs to express PNP for total cell death to occur. 17, 19 Second, cell-to -cell contact is not required for 6MP killing. 6MP released by PNP -GDEPT -induced cell death is taken up by and kills nearby cells. 19 Third, 6MP -treated cell lines show inhibition of protein, RNA, and DNA syntheses, whereas FU primarily inhibits DNA synthesis. 20 Fourth, in vitro, 6MP is toxic to nonproliferating cells after 10 -24 hours of treatment when FU has little effect. Lastly, 6MP is a more potent toxin than either GCV triphosphate or FU, 21 leading to tumor regression at prodrug concentrations at which GCV and FU would have little effect. Thus, the PNP -GDEPT system has the attributes necessary to induce antitumor activity, particularly against slow -growing tumors where the percentage of proliferating cells is low. 22 Ad vectors can transduce both dividing and nondividing cells to achieve efficient, transient gene expression in vitro and in vivo. We previously used a recombinant Adexpressing PNP from a 630 -bp promoter fragment derived from the prostate -specific antigen (PSA ) gene (Ad5 -PSA -PNP ) together with 6MPDR to assess the potential of this GDEPT system. Although the promoter fragment lacked prostate specificity and had only low activity in the target cells, we suppressed prostate cancer growth in vitro 18 and in vivo.
23 PC -3 cells transduced with Ad5 -PSA -PNP were killed in 7 -14 days by nontoxic levels of 6MPDR. 18 A single intratumoral injection of Ad5 -PSA -PNP into PC -3 tumors growing s.c. in BALB /c nude mice followed by 6MPDR treatment reduced tumor growth at day 52 by $75% compared with controls and increased mouse survival; 20% of PNP -GDEPT -treated mice lived >448 days longer than controls. One level of prostate targeting can be obtained by injecting the gene vector directly into the tumor. Additional specificity may be achieved by controlling therapeutic gene expression with prostate -specific gene regulators. We have examined the activity and specificity of the human PSA, rat probasin (Pb ), and relaxin H2 gene promoters. 24 The Pb and PSA elements show strong androgen -inducible expression in various prostate cell lines with limited expression in nonprostate cell types in vitro, but both require active androgen receptor (AR ) for activity. 24 Studies by Schuur et al, 32 Pang et al, 25 Zhang et al, 33 and Cleutjens et al 50 have shown that PSA expression is controlled by two functional domains -a proximal promoter and a distal enhancer region (PSE ) -both of which are androgen -responsive. The addition of the upstream PSE region strongly enhanced promoter activity in LNCaP cells, but activity was still minimal in PC3 cells, which lack the AR. 24 Here we show that modification of the Pb promoter using the SV40 enhancer has removed its androgen dependence, and such constructs show high -level expression in various prostate cancer cell lines without loss of specificity. 26 We further show the utility of a recombinant Ad5 vector carrying the SVPb -PNP cassette in treating human prostate tumors in an animal model.
Materials and methods

Cell lines and cell culture
PC -3, DU -145, and TsuPr androgen -independent prostate cancer cell lines and MCF -7 breast cancer cells were obtained from ATTC (Rockville, MD ), and androgensensitive LNCaP cells were obtained from Professor L Chung ( University of Virginia, Charlottesville, VA ); HepG2 cells were from Dr G Schreiber (Melbourne University, Melbourne, Australia ); human 293 embryonic kidney cells from Dr F Graham ( Hamilton, Ontario, Canada ), MRC-5, and CHO K1 cells from Dr R Holliday ( CSIRO Molecular Science, North Ryde, NSW, Australia ) and UCRU -BL -13 ( abbreviated BL -13) 44 were developed in our laboratory. LNCaP cells were maintained in T medium. 45 PC -3, MCF -7, and BL -13 cells were grown in RPMI medium 1640 ( Invitrogen, Life Technologies, Grand Island, NY ) containing 2 mM L -glutamine (Invitrogen, Life Technologies ), 0.2 M HEPES buffer solution ( Invitrogen, Life Technologies ), 0.85 g/ L NaHCO 3 ( Sigma, St. Louis, MO ), 2 U /mL penicillin G, 100 g /mL streptomycin sulfate ( Invitrogen, Life Technologies ), and 10% fetal bovine serum ( FBS; TRACE Biosciences, Clayton, Australia ). HepG2 and MRC -5 cells were maintained in Dulbecco's modified essential medium (Invitrogen, Life Technologies ) containing 2 mM glutamine, 0.45% glucose, and 10% FBS. CHO and 293 cells were maintained in MEM ( Invitrogen, Life Technologies ) containing nonessential amino acids and 10% FBS. The cells were free of mycoplasma and used in log phase. Cells were harvested with 0.125% trypsin /1.3 mM EDTA -4Na (Invitrogen, Life Technologies ).
Nude mice
Male BALB /c nu /nu (''nude'' ) mice aged 6 -18 weeks were used for all experiments. Animals were bred at Cancer Gene Therapy 
Plasmids
Promoter and enhancer constructs were cloned in front of the chloramphenicol acetyltransferase gene in the pCATSAT reporter plasmid. 24 Pb sequences from À 426 (HindIII ) to +26 (SacI) were cloned into the SacI site of pBluescriptSK + and then recloned as a HindIII -to -XbaI fragment into pCATSAT. SV40 enhancer sequences were isolated as a 250 -bp BstYI fragment from the plasmid pCAT enhancer ( Promega, Madison, WI ) subcloned BamHI -cut pBluescriptSK + ( Stratagene, La Jolla, CA ), then recloned as a XbaI-to -KpnI fragment into pUC19. It was then excised as a HindIII fragment and cloned into the HindIII site of Pb430CATSAT to give the plasmids SVaPb430CATSAT and SVbPb430CATSAT. The ''a'' and ''b'' orientations of the enhancer are distinguished by the position of the NcoI site near one end of the enhancer, as indicated in Figure 1 .
Transfections
Prostate -specific promoter activity was measured following transfection of plasmids containing the chloramphenicol acetyl transferase (CAT ) gene under the SVPb promoter and a reference gene, serine acetyl transferase ( SAT ), under the control of the RSV promoter. CAT and SAT assays were conducted as described previously. 24 The ratio of expression from RSVCAT and RSVSAT in the control transfections in each experiment was used to normalize promoter activities relative to the RSV promoter. In some experiments, a plasmid expressing the AR gene under the control of the human cytomegalovirus promoter was cotransfected with pCATSAT plasmids into PC -3 cells as described. 24 Recombinant adenovirus production A replication-deficient human recombinant type -5 adenovirus (Ad5 ) carrying the E. coli DeoD gene linked to a 630-bp PSA promoter was constructed as described previously. 18, 23 An expression cassette, in which the SV40 enhancer and rat probasin promoter (SVPb ) replaced the PSA promoter, was constructed as follows. The SVPb element in plasmid SVPb /CAT /SAT was excised as a SalI/XbaI fragment and blunt -ended. The pXCX3 -based plasmid carrying the PSA /PNP cassette 18, 23 was cut with HindIII / KpnI to release the PSA promoter, blunted, and religated. The new plasmid was cut with SpeI, blunt -ended, dephosphorylated, and ligated with the blunted SalI/XbaI fragment from above. The correct orientation was selected. A recombinant Ad5 vector carrying the SVPb /PNP cassette in the E1 region was constructed by recombination in 293 cells as previously described. 18, 23 Recombination between plasmids pXCX2 46 and pJM17 47 was used to rescue a control virus, MX17, that carried the same flanking sequences but lacked an expression cassette. Plaques were picked, virus stocks were grown, and their genomes were confirmed as correct by restriction enzyme digestion. Viruses were propagated in 293 cells and purified by banding on CsCl density gradients, followed by dialysis. 47 
Prodrugs
The deoxyadenosine analogue, 6MPDR, was synthesized as previously described, 48 purified by HPLC chromatography and stored at À 208C. 
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Targeted prostate cancer gene therapy R Martiniello -Wilks et al GDEPT in vitro 6MPDR was used at 50 M for in vitro studies. Virusinduced activity in cell killing in the presence of 50 M 6MPDR was measured by the decrease in metabolic activity as determined by Alamar Blue assays, 18 relative to the virusalone -infected controls (metabolic activity [% control ] ). To determine the impact of 6MPDR on uninfected cells, the metabolic activity of 6MPDR -treated cells was determined relative to uninfected cells (0 MOI, multiplicity of infection ).
Gene -directed enzyme -directed prodrug therapy in vivo Doses of 6MPDR that were nontoxic in vivo were determined in preliminary experiments ( data not shown ). Tumors were generated by injecting 1.5Â10 6 PC -3 cells s.c. in adult male BALB / c ''nude'' mice. Once the tumor volume reached approximately 5Â5 mm, mice were anaesthesized by inhalation anaesthetic (isoflurane carried in O 2 ; Abbott Australasia, Redwood City, CA ), and 20 L (4Â10 8 pfu in PBS ) of either recombinant, Ad5 -SVPb -PNP, or control virus MX17 was directly injected into the tumors using 0.25 -mL disposable syringes with a 29-gauge 1 /2 -in. needle ( Terumo, Elkton, MD ). The needle point was moved to various sites within the tumor during injection to maximize the area exposed to virus. Following virus injection (day 0 ), mice were treated intraperitoneally ( i.p. ) with prodrug 6MPDR at 5 mg /kg twice daily for 6 days ( days 1-6 ). Previously, we have assessed the persistence of PNPase expression in s.c. murine prostate RM -1 tumors following injection ( day 0) with an adenoviral vector carrying PNP (Voeks et al, submitted ). The adenoviral vector used carried the PNP gene under the control of the powerful Rous Sarcoma virus (RSV ) promoter. In these studies, animals were sacrificed 1, 2, 3, 4, and 6 days following vector injection. At each time point, four animals were sacrificed, tumors were harvested, and homogenized. Equal amounts of protein from each tumor ( 500 g) were assayed for PNPase conversion of 6MPDR to 6MP in a 2.5-hour assay. The level of conversion was measured using reverse-phase HPLC. Maximal 6MPDR conversion was observed in tumor lysates harvested 1 day following vector injection ( $80% ). This PNPase activity diminished over time with only 20% conversion remaining in those tumors harvested on day 6. These results showed that maximal tumor PNPase expression was observed within 4 days following vector injection. Thus, prodrug treatment in our subsequent PNP -GDEPT studies was maintained over a 5 -to 6 -day period following adenoviral injection.
Groups of 10 mice received ( a) nil vector / nil 6MPDR; these mice were treated with PBS; (b ) Ad5 -SVPb -PNP alone; ( c) MX17 plus 6MPDR; or ( d) Ad5 -SVPb -PNP plus 6MPDR. Mice were sacrificed when they exhibited signs of distress ( a rare event ) or when the tumor reached a size of 15Â15 mm or when body weight loss exceeded 20%. At sacrifice, a portion of the tumor and several organs, including draining lymph nodes, liver, spleen, kidney, lung, and gut, were fixed from three animals per group for histological evaluation of possible toxic damage due to the GDEPT.
Assessment of in vivo tumor growth
Tumors were measured using vernier calipers twice weekly across two diameters, d 1 and d 2 , at right angles, and the volumes ( V ) of the tumors were calculated: V= / 6(d 1 xd 2 ) 3 / 2 , as previously described. 49 Data were presented as mean tumor volume ± SEM versus time (days post vector injection ) when >30% of mice was alive in each treatment group. A line of best fit was then generated for each treatment curve using Microsoft EXCEL software for PC. The days ( t) taken to reach the midpoint of maximal PC -3 tumor growth was then extrapolated from the point where the line of best fit intersects the midpoint of maximal tumor growth. This was determined for each treatment group. The ability of the treatment to suppress tumor growth was then determined as follows: % Reduction in tumor growth
In this study, all treatments were compared to the nil vector / nil 6MPDR control group.
Statistical analysis
Individual tumor volumes for treated and control mice were compared over the time course of each experiment using the nonparametric one-way Kruskal -Wallis ANOVA. Treatment groups showing a significant difference in growth were identified using Dunn's post -test. Tumor volume data were Cancer Gene Therapy Prince Alfred Hospital, Sydney, NSW, Australia ), by studying the microscopic appearance of the cells and the presence of apoptotic bodies.
Results
Tissue specificity of the SV40PB promoter in vitro
The core 430-bp promoter ( Pb) was previously shown to confer androgen-inducible, prostate -specific expression both in vitro and in transgenic mice. 27 -29 To increase its activity, we linked the SV40 enhancer (SV ) to Pb and evaluated its activity and specificity in a series of transfection For each cell line, combined results of at least two independent experiments were presented as mean metabolic activity ( % control ) ± SD.
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Targeted prostate cancer gene therapy R Martiniello -Wilks et al experiments. The activity of Pb, alone or in combination with the SV40 enhancer (SVaPb and SVbPb for the two enhancer orientations ), was measured following transfection of plasmids (Fig 1) containing the elements in front of the CAT gene and a reference gene cassette, SAT, under the control of the RSV promoter. Expression levels were normalised to that of the RSV promoter. The activities of the Pb promoter in concert with different arrangements of the SV40 enhancer in various cell types are shown in Figure 2 . The promoter alone showed low activity in the LNCaP and DU145 prostate cell lines and negligible activity in the PC -3 and TsuPr androgen -independent prostate cancer cell lines. Cotransfection of the AR into the AR -deficient PC -3 cells led to a strong stimulation of expression, indicating the critical androgen dependence of the promoter. Among the nonprostate cell lines, slight activity was seen in the MCF -7, breast, and HepG2 liver cell lines. For both enhancer -containing constructs, increased expression was seen in both prostate and nonprostate cell types. In the androgen -sensitive line, LNCaP, this increase was relatively modest, about 5 -fold. The most dramatic increase was seen in the androgenindependent prostate cancer cell lines where expression ranged between 10% and 60% of that of the RSV promoter. This high -level expression was seen in the absence of cotransfection of the AR. Indeed, when the AR was cotransfected into PC -3 cells, activity was generally found to be lower, perhaps reflecting competition between binding factors or stimulatory pathways. The highest expression in nonprostate cell types was seen in cell lines of secretory epithelial origin such as MCF -7 ( breast cancer ) and BL13 ( bladder cancer ) lines. (Note that the AR is expressed in the MCF -7 line.) Expression in the other cell lines, such as 293 ( kidney ), MRC -5 (lung fibroblast), and HepG2 (liver ), was much lower, e.g., at least 20 -fold, for the SVbPb construct. Other experiments have shown that Pb can also be activated by AR gene cotransfection in most nonprostate cell lines. Similarly, as observed in PC -3 cells, the different SVPb combinations showed little or no requirement for AR gene cotransfection. Thus, the SVPb enhancer / promoter combinations control substantially specific expression in androgen -independent prostate cells relative to other cell types.
PNP -GDEPT in vitro
Recombinant Ad5 viruses expressing PNP from a 630-bp PSA promoter ( Ad5 -PSA -PNP ) 18 or SVbPb (Ad5 -SVPb -PNP ) were constructed (Fig 1 ) . PC -3, MRC, or HepG2 cell lines were transduced with different MOI of these viruses. Cultures were incubated for 6 days in the presence of 50 M 6MPDR and metabolic activity was assayed using the Alamar Blue assay. 18 The Ad5 -SVPb -PNP vector ( Fig 3A ) showed increased killing of PC -3 cells and at lower MOI than the Ad5 -PSA -PNP vector ( Fig 3B ) . However, killing of MRC -5 and HepG2 was not substantially increased. The killing of prostate PC -3 cells by Ad5 -SVPb -PNP was some 10-to 20-fold greater than in HepG2 cells or MRC -5 cells in vitro, indicating that substantial prostate -specific expression was achieved in vitro in the context of an adenovirus backbone.
PNP -GDEPT in vivo
We previously demonstrated that intratumoral injection of PC -3 tumor-bearing mice with Ad5 -PSA -PNP (10 9 pfu ) produced PNP activity in tumor lysates, caused substantial inhibition of tumor growth, and increased mouse survival. 23 Preliminary experiments were also performed to determine whether 6MPDR alone ( 5 mg / kg) had any effect on PC -3 tumor growth. Mice treated with nil vector /nil prodrug or Figure 4 Effects of Ad5 -SVPb -PNP plus 6MPDR GDEPT on s.c. PC -3 tumor growth in nude mice. Following vector injection ( day 0 ), mice were treated i.p. with 6MPDR at 5 mg / kg twice daily for six consecutive days ( days 1 -6 ). Data were presented as mean tumor volume ± SEM versus time ( days postvector injection ) when >30% of mice was alive in each treatment group. Treatments included: nil vector / nil 6MPDR ( n = 11 ), MX17 alone ( n = 10 ), Ad5 -SVPb -PNP alone ( n = 8 ), MX17 plus 6MPDR ( n = 10 ), Ad5 -SVPb -PNP plus 6MPDR ( n = 10 ).
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Targeted prostate cancer gene therapy R Martiniello -Wilks et al 6MPDR alone showed no difference in tumor growth ( P= .11; data not shown ). This study examines the therapeutic efficacy of Ad5 -SVPb -PNP plus 6MPDR in vivo. PC -3 tumor-bearing nude mice were treated by intratumoral injection with buffer, control Ad5 vector, MX17, lacking the expression cassette, or Ad5 -SVPb -PNP at a lower dose ( 4Â10 8 pfu ) than previously used, on day 0. These mice then received 6MPDR treatment i.p. for 6 days. Mouse weights and tumor volumes were recorded twice weekly. Data were presented as mean tumor volume ± SEM versus time (days post vector injection ). The effects of GDEPT on tumor growth are shown in Figure 4 . When compared to the nil vector /nil prodrug group, control treatments of MX17 used alone ( À 3% ), Ad5 -SVPb -PNP used alone (3% suppression), or MX17 plus 6MPDR (8% suppression ) showed negligible effects on PC -3 tumor growth. Treatment with Ad5 -SVPb -PNP plus 6MPDR significantly reduced PC -3 tumor growth by 49% (P <.01 vs. MX17 alone ) following analysis using the Kruskal -Wallis one-way ANOVA for nonparametric data and the Dunn's post -test.
The survival of treated tumor-bearing mice was also extended (Fig 5 ) . PC -3 tumor-bearing mice treated with 6MPDR alone, or control vector MX17 plus 6MPDR, were all dead by day 70, whereas 33% of mice treated with Ad5 -SVPb -PNP plus 6MPDR was still alive at this time and persisted for up to 101 days. One surviving mouse in this group displayed a tumor that remained static at 5Â5 mm in size for the duration of the study (104 days ), indicative of a cure. However, one surviving mouse treated with MX17 alone also displayed a 5Â5 -mm tumor that remained static for the duration of the study. Thus, treatment with Ad5 -SVPb -PNP plus 6MPDR offered an overall survival advantage of $20% over control animals.
To evaluate the mechanism(s) of tumor suppression, the level of apoptosis and necrosis in tumor tissue following GDEPT was investigated as previously described. 10 Tissues including the tumors from three mice of each experimental group were stained with haematoxylin and eosin and examined histologically. Evidence of apoptosis was assessed by an experienced histopathologist who studied the microscopic appearance of the cells and looked for the presence of apoptotic bodies. Apoptotic bodies were rarely seen in any tumor whether from a treated or control group. In contrast, varying degrees of necrosis (10 -80% ) were observed in all tumors examined. The extent of necrosis did not appear to be related to any treatment. Tumor tissue from three mice treated with Ad5 -SVPb -PNP plus 6MPDR showed 33.3% necrosis, which was only marginally higher than that in tumors from control mice (mean of 28.3% necrosis ). Some infiltration of polymorphs was occasionally seen in necrotic areas, and there was minimal infiltration of lymphocytes at the periphery of the tumors. The level of infiltration was no different in GDEPT-treated tumors from that seen in controls ( nil vector /nil 6MPDR; control MX17 vector alone, MX17 plus 6MPDR ). No infiltrate was seen throughout the body of the tumor. Histological assessment of other tissues, including liver, spleen, kidney, lung, and gut, showed no changes indicative of toxic damage.
Discussion
Adenoviruses have previously been used to deliver the HSVTK gene under the control of the strong, but nonspecific, RSV promoter to rodent RM -1 prostate tumors in vivo. 10 A similar system was recently used in a phase I/II clinical trial in men with prostate cancer, 13 with promising Cancer Gene Therapy 20 This may be advantageous for slow -growing tumors, such as prostate, 22 but requires that the activity of the GDEPT system should be restricted to the target cells. The wide host range of adenoviruses further compounds the problem. In principle, targeting can be achieved by controlling gene expression with a tumor-specific promoter and/ or by modifying the virus particle to restrict its tissue tropism. 30, 31 As the prostate is ''dispensible,'' tissue -specific, rather than tumor-specific, gene expression can be used. The production of prostatespecific vectors may in the future allow for the treatment of metastatic prostate cancer by the delivery of these vectors systemically.
This study describes a recombinant vector in which we have focused on control at the level of gene expression. We previously used a basal PSA promoter in an initial attempt to achieve prostate -specific delivery of either the HSV-TK or PNP genes. In vitro, the PNP -GDEPT system was more efficient and provided faster prostate cancer cell killing than the TK -GDEPT system using the same PSA promoter. 18 However, in vivo, both systems gave comparable results. Thus, we obtained a 75% reduction in tumor growth with a cure in 20% of treated mice. 23 Recent studies have identified a prostate -specific enhancer element (PSE ) upstream of the PSA gene, which provided increased levels of expression and improved specificity compared with the core PSA promoter. 32, 34 This regulatory, element together with the proximal PSA promoter or a longer, more active promoter from the rat Pb gene, 35, 36 showed significantly better androgen -inducible, prostate -specific activity than the core PSA promoter used in our previous study. However, they require androgen and expression of the AR for maximum activity. 24 We have recently characterized an enhancer, PSMe, from the prostate -specific membrane antigen gene that provides strong, androgen-independent activation of transcription in the LNCaP and LA -PC4 prostate cells lines, but its activity is low or absent in the androgen -independent lines PC -3 and DU145. 51 In the current paper, we have used a new control element in which the Pb promoter was combined with the SV40 enhancer to create SVPb. The element does not require androgen for maximal expression, and exhibits strong activity in androgen -independent prostate cell lines such as PC -3 and DU145 and a substantial level of prostate specificity.
In the context of virally delivered GDEPT, the SVPb provided substantially improved activity in prostate cells compared with the PSA promoter, and showed significant selectivity for prostate cells in vitro (Fig 3) . Ad5 -SVPb -PNP provided equivalent killing of prostate PC -3 cells at a 10 -fold -lower vector input than observed with Ad5 -PSA -PNP ( Fig 3, A and B ) . Such differential killing was not seen for the nonprostate cells, MRC -5 and HepG2, and vector inputs required for equivalent cell killing were 5-to 10 -fold higher than for the PC -3 prostate cell line (Fig 3, A and B ) .
Our in vivo studies showed that Ad5 -SVPb -PNP with 6MPDR suppressed the growth of PC -3 xenografts in nude mice significantly (Fig 4 ) , whereas this was not affected by control treatments, including MX17 used alone, Ad5 -SVPb -PNP used alone, or MX17 plus 6MPDR. All mice treated with nil vector / nil prodrug had died by day 70, whereas 33% of mice which received Ad5 -SVPb -PNP plus 6MPDR was still alive at this time and persisted for up to 101 days (Fig 5) . One surviving mouse in this group displayed a tumor that remained static at 5Â5 mm in size for the duration of the study (which was terminated due to relocation of the animal facility). In our previous study in which the therapeutic efficacy of Ad5 -PSA -PNP plus 6MPDR was assessed in PC -3 tumor-bearing nude mice, tumor growth was $75% less than in control mice on day 52, and 20% of these mice remained alive for >448 days longer than controls. 23 This contrast in results may be attributable to the use of a lower dose ( 4Â10 8 pfu /tumor ) of recombinant vector in the present study than that previously used ( 10 9 pfu /tumor ). It has previously been shown that substrate limitation could be an issue where s.c. tumors are concerned. Thus, when the TK -GDEPT was used in micebearing s.c. tumors, doses of GCV at 50 -100 mg /kg /day were required, 10,37,38 whereas mice carrying i.p. tumors transduced with vector and then treated with GCV i.p. required only 5 -50 mg /kg /day GCV. 39, 40 The dose of 6MPDR used in these experiments (5 mg /kg twice daily for 6 days ) 23 was also much lower than the maximum tolerated dose ( 67 mg /kg daily for 3 days ) reported previously for nude mice. 41 Thus, our results might have been further improved if a higher dose of prodrug had been used.
Histological analysis of PC -3 tumor sections from mice treated with Ad5 -SVPb -PNP plus 6MPDR revealed only a minimal level of lymphocytic infiltration, and this did not differ from that seen in controls. The tumor infiltration was confined to the periphery of the tumor. These results contrast with those described by us previously 23 when PC -3 tumors were treated with Ad5 -PSA -PNP plus 6MPDR and with those of Eastham et al, 10 in which lymphocytic infiltration into prostate tumors was observed with the HSVTK / GCV system. The difference may relate to the lower vector dose used in this work (4Â10 8 vs. 10 9 pfu ). Metastatic cells were observed in the subcapsular sinus of draining lymph nodes, throughout the lymph node, or in one case in the afferent lymphatics of the lymph node of 5/ 6 control mice, and in 3 /3 mice treated with Ad5 -SVPb -PNP plus 6MPDR. There was no evidence of metastasis in other tissues studied, including, liver, spleen, kidney, lung, and gut and no other changes indicative of toxic damage were seen when these organs were histologically assessed.
Gene therapy approaches have the advantage that they may be used in concert with other strategies, such as those which enhance antitumor immunity. Under those conditions, GDEPT may be even more effective given that the immune response is stimulated at the site of cell killing, seeding immune cells that can migrate to metastatic sites. 42, 43 The combination of GDEPT with immune -enhancing strategies should theoretically control both local and metastatic disease. The use of repeated, rather than single, injections of vector and the use of vectors in tandem or in combination with cytokine gene expression should also lead to enhanced effectiveness. The availability of a control element that
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Targeted prostate cancer gene therapy R Martiniello -Wilks et al functions in an androgen -independent manner raises the possibility that GDEPT may be used in conjunction with hormone ablation therapy to provide supplementary treatment for emerging androgen -independent disease when the tumor burden is low.
